Dr. Jonathan R. Strosberg on 177-Lu-Dotatate in Patients With Neuroendocrine Tumors

Video

Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the targeted, systemic radiation treatment 177-Lu-Dotatate (Lutathera), a somatostatin analogue peptide, in patients with neuroendocrine tumors.

Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the targeted, systemic radiation treatment 177-Lu-Dotatate (Lutathera), a somatostatin analogue peptide, in patients with neuroendocrine tumors. Strosberg says this targeted therapy is especially useful due to neuroendocrine tumors generally having high-expressing somatostatin expressers.

Recent Videos
Related Content
Ocular Events With Mirvetuximab Show No Impact on QoL in Ovarian Cancer

Ocular Events With Mirvetuximab Show No Impact on QoL in Ovarian Cancer

Jordyn Sava
March 31st 2025
Article

Read More

LaPelusa’s Journey in the Dynamic Field of GI Oncology

LaPelusa’s Journey in the Dynamic Field of GI Oncology

Jordyn Sava;Michael LaPelusa, MD
May 1st 2024
Podcast

In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.

Listen

Teclistamab, Daratumumab, Pomalidomide Is Feasible in Multiple Myeloma

Teclistamab, Daratumumab, Pomalidomide Is Feasible in Multiple Myeloma

Jordyn Sava
March 22nd 2025
Article

Anita D'Souza, MD, discussed the results from the MajesTEC-2 and TRIMM-2 trials in patients with multiple myeloma.

Read More

Unpacking the Latest Research in Gastrointestinal Cancers

Unpacking the Latest Research in Gastrointestinal Cancers

Nichole Tucker;Benjamin L. Schlechter, MD
February 15th 2023
Podcast

In season 4, episode 1 of Targeted Talks, Benjamin L. Schlechter, MD, discuses new studies in the gastrointestinal cancers space.

Listen

Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond

Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond

Jonah Feldman
March 21st 2025
Article

Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.

Read More

FDA Grants Standard Approval to Pembrolizumab Plus Trastuzumab/Chemo for HER2+, PD-L1+ Gastric Cancer

FDA Grants Standard Approval to Pembrolizumab Plus Trastuzumab/Chemo for HER2+, PD-L1+ Gastric Cancer

Jordyn Sava
March 19th 2025
Article

The combination of pembrolizumab, trastuzumab, and chemotherapy is now approved in HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.

Read More